Medicines for end of life and rare conditions
Following an extensive review, the SMC has changed the way it evaluates end of life medicines and medicines to treat rare conditions. Pharmaceutical companies are able to request that SMC convenes a Patient and Clinician Engagement (PACE) meeting.
The PACE process gives patient groups and clinicians a stronger voice in SMC decision making. The documents below provide more detail and help explain what can be expected from the PACE meeting.
Find out more about patient group participation in our PACE meetings
Watch Patient Group Partner Nic White talk about how patient groups are involved in our PACE meetings